Latest Vascular endothelial growth factor Stories
CRANBURY, N.J., April 15, 2015 /PRNewswire/ -- Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development
LONDON, April 6, 2015 /PRNewswire/ -- Report DetailsAnalysis of revenues and R&D prospects for those eye drugs - you explore potentialsWhat's the future for treating disorders
Efficacy and Safety of Long-term, Continuous Anti-VEGF will be Assessed in Phase 2 Study CUMBERLAND, R.I., March 30, 2015 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc.
Market Publishers Ltd informs that new reports by GlobalData have been recently uploaded to its catalogue. London, UK (PRWEB) March 25, 2015 Market Publishers
Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., March 25, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" market research
RnRMarketResearch.com adds “Avastin (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023” to its store. Dallas, Texas (PRWEB)
SAN DIEGO, March 16, 2015 /PRNewswire/ -- Gensignia Life Sciences, Inc., (Gensignia) a molecular diagnostics company specializing in microRNA (miRNA) signatures as cancer diagnostic
TARRYTOWN, N.Y., Feb. 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
In patients with moderate or worse vision loss at baseline, those treated with EYLEA gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.